Cancer therapy with vaccination using HLA-A24-restricted peptide from human vascular endothelial growth factor receptor 2: a phase I study in patients with unresectable colorectal cancer
Not Applicable
- Conditions
- unresectable colorectal cancer
- Registration Number
- JPRN-UMIN000000704
- Lead Sponsor
- Institute of Medical Science, University of Tokyo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
pregnancy uncontroled infection uncontroled cerebral metastasis etc,
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method